Short- and Mid-Term Effects of Empagliflozin on Sodium Balance and Fluid Regulation in Chronic Heart Failure
Mid-range effects of empagliflozin in heart failure with reduced EF include transient natriuresis and sustained glucosuria, with compensatory reductions in FWC. Reductions in skin sodium content were maintained, and volume homeostasis in CHF patients stabilized after 3 months.
Authors
- Stephan Achenbach (ORCID: https://orcid.org/0000-0002-7596-095X)
- Kristina Striepe
- Roland Erich Schmieder (ORCID: https://orcid.org/0000-0003-2356-5883)
- Dennis Kannenkeril (ORCID: https://orcid.org/0000-0002-2345-238X)
- Armin Michael Nagel (ORCID: https://orcid.org/0000-0003-0948-1421)
- Mario Schiffer (ORCID: https://orcid.org/0000-0002-8414-1470)
- Julie Kolwelter
- Peter Linz (ORCID: https://orcid.org/0000-0002-8232-1443)
- Michael Uder (ORCID: https://orcid.org/0000-0001-6238-4247)
- Agnes Bosch (ORCID: https://orcid.org/0000-0001-6952-4660)
- Venera Bytyqi (ORCID: https://orcid.org/0009-0000-9650-9220)
- Marina V. Karg
Institutions
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Universitätsklinikum Erlangen (DE)
- Comprehensive Cancer Center Erlangen (DE)
Publication Details
- Journal
- European Journal of Heart Failure
- Published
- 2025-11-04
- DOI
- https://doi.org/10.1002/ejhf.70078
- Citations
- 2
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 2.59